EPS Creative Health Technology Group publishes 2025/2026 annual report

• EPS Creative Health Technology Group published its annual report for the year ended March 31, 2026, flagging a shift toward profit-focused operations.
• Healthcare and medicated products expanded, with health and medicated food distribution growing on new sales channels; lab supply distribution stayed steady despite yen weakness.
• Garment business weakened as US-based demand fell; the segment’s top customer stopped placing orders during the year.
• China IRO with CRO service narrowed its scope and customer targets, cutting segment losses; the group also began preparations for new revenue lines.
• Management highlighted portfolio optimization, with earlier exits from Japan IRO and in-house R&D, while exploring entry into cosmetics via a February 2025 minority stake.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EPS Creative Health Technology Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260720-12249320), on July 20, 2026, and is solely responsible for the information contained therein.